A critical view of the BJH publication on the lack of benefit of second‐line daratumumab in patients with functional high‐risk multiple myeloma | Synapse
April 27, 2026
A critical view of the BJH publication on the lack of benefit of second‐line daratumumab in patients with functional high‐risk multiple myeloma
Key Points
The aim is to critically analyze the benefits of second-line daratumumab in patients with functional high-risk multiple myeloma.
Analyzed existing literature on daratumumab effectiveness in high-risk multiple myeloma without generating new data.
Focused on evaluating patient outcomes and treatment efficacy.
No new datasets were generated or analyzed, limiting the ability to conclude on treatment benefits.
Abstract
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.